A NEW FUNCTIONAL CYP3A4 POLYMORPHISM (CYP3A4*22) IS ASSOCIATED WITH INCREASED RISK OF DELAYED GRAFT FUNCTION AND WORSE RENAL FUNCTION IN CYCLOSPORIN-TREATED KIDNEY TRANSPLANT RECIPIENTS.

被引:0
|
作者
Elens, L. [1 ]
Bouarmar, R. [2 ]
Hesselink, D. A. [3 ]
Haufroid, V. [4 ]
van Gelder, T.
van Schaik, R. H. [1 ,3 ]
机构
[1] Erasmus MC, Dept Clin Chem, Rotterdam, Netherlands
[2] Erasmus MC, Dept Hosp Pharm, Rotterdam, Netherlands
[3] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands
[4] Catholic Univ Louvain, Louvain Ctr Toxicol & Appl Pharmacol, B-1200 Brussels, Belgium
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
引用
收藏
页码:S107 / S107
页数:1
相关论文
共 50 条
  • [41] Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients
    Zochowska, Dorota
    Wyzgal, Janusz
    Paczek, Leszek
    ANNALS OF TRANSPLANTATION, 2012, 17 (03) : 36 - 44
  • [42] Dosing algorithm for Tacrolimus in Tunisian Kidney transplant patients: Effect of CYP 3A4*1B and CYP3A4*22 polymorphisms
    Ben-Fredj, Nadia
    Hannachi, Ibtissem
    Chadli, Zohra
    Ben-Romdhane, Haifa
    Boughattas, Naceur A.
    Ben-Fadhel, Najah
    Aouam, Karim
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2020, 407
  • [43] Influence of Renal Function on Pharmacokinetics of Antiepileptic Drugs Metabolized by CYP3A4 in a Patient With Renal Impairment
    Yamamoto, Yoshiaki
    Usui, Naotaka
    Nishida, Takuji
    Mori, Miho
    Takahashi, Yukitoshi
    Imai, Katsumi
    Kagawa, Yoshiyuki
    Inoue, Yushi
    THERAPEUTIC DRUG MONITORING, 2018, 40 (01) : 144 - 147
  • [44] Influence of CYP3A4*1B and CYP3A5*1 polymorphisms on tacrolimus exposure in Tunisian kidney transplant recipients
    Ben Fredj, N.
    Kerkni, E.
    Baptiste, W. Jean
    Chaabane, A.
    Hammouda, M.
    Kolsi, A.
    Skhiri, H.
    Boughattas, N.
    Aouam, K.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2015, 29 : 62 - 62
  • [45] CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort
    Kitzmiller, Joseph P.
    Luzum, Jasmine A.
    Baldassarre, Damiano
    Krauss, Ronald M.
    Medina, Marisa W.
    PHARMACOGENETICS AND GENOMICS, 2014, 24 (10): : 486 - 491
  • [46] CYP3A4/5 polymorphisms affect the blood level of cyclosporine and tacrolimus in Chinese renal transplant recipients
    Li, Dan-ying
    Teng, Rui-chen
    Zhu, Huai-jun
    Fang, Yun
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2013, 51 (06) : 466 - 474
  • [47] ASSOCIATION OF CYP3A4*18B POLYMORPHISMS WITH THE PHARMACOKINETICS OF TACROLIMUS IN CHINESE RENAL TRANSPLANT RECIPIENTS
    Li Danying
    Fang Yun
    Teng Ruichen
    PROGRESS ON POST-GENOME TECHNOLOGIES AND MODERN NATURAL PRODUCTS, 2011, 2011, : 250 - 252
  • [48] Prediction of tacrolimus metabolism and dosage requirements based on CYP3A4 phenotype and CYP3A5*3 genotype in Chinese renal transplant recipients
    Xi Luo
    Li-jun Zhu
    Ning-fang Cai
    Li-yun Zheng
    Ze-neng Cheng
    Acta Pharmacologica Sinica, 2016, 37 : 555 - 560
  • [49] Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis
    Zuo, Xiao-cong
    Ng, Chee M.
    Barrett, Jeffrey S.
    Luo, Ai-jing
    Zhang, Bi-kui
    Deng, Chen-hui
    Xi, Lan-yan
    Cheng, Ke
    Ming, Ying-zi
    Yang, Guo-ping
    Pei, Qi
    Zhu, Li-jun
    Yuan, Hong
    Liao, Hai-qiang
    Ding, Jun-jie
    Wu, Di
    Zhou, Ya-nan
    Jing, Ning-ning
    Huang, Zhi-jun
    PHARMACOGENETICS AND GENOMICS, 2013, 23 (05): : 251 - 261
  • [50] The Impact of CYP3A4*22 on Tacrolimus Pharmacokinetics and Outcome in Clinical Practice at a Single Kidney Transplant Center
    Abdel-Kahaar, Emaad
    Winter, Stefan
    Tremmel, Roman
    Schaeffeler, Elke
    Olbricht, Christoph J.
    Wieland, Eberhard
    Schwab, Matthias
    Shipkova, Maria
    Jaeger, Simon U.
    FRONTIERS IN GENETICS, 2019, 10